Pharmamarketeer

Roche gets NICE approval for advanced bladder cancer

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment is still gaining ground with regulators for its initial treatment focus in bladder cancer.

Reageer

Medhc-fases-banner
Advertentie(s)